Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

SA Transcripts 161.79K Followers Follow Inovio Pharmaceuticals, Inc. ( INO ) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDT Company Participants Jennie Willson - Director of Communications Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer & Head of Development Steven Egge - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Liang Cheng - Jefferies LLC, Research Division Katherine Degen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Wednesday, August 12, 2026. I would now like to turn the conference over to Jennie Willson, Director of Communications. Please go ahead. Jennie Willson Director of Communications Thank you. Good afternoon, and thank you for joining the Inovio Second Quarter 2026 Financial Results Conference Call. Joining me today are Dr. Jacqui Shea, President and Chief Executive Officer; Dr. Michael Sumner, Chief Medical Officer; Steven Egge, Chief Commercial Officer; and Peter Kies, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended June 30, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These statements relate to our business plans to develop Inovio's DNA medicines platform, including the FDA's ongoing review of our BLA for INO-3107, including the October 30, 2026, PDUFA target date and our recently completed informal meeting with the FDA, our belief that INO-3107 fulfills the criteria for accelerated approval, the potential benefits of INO-3107, including our belief that it has a positively differentiated product profile, our belief regarding its competitive advantages relative to existing treatments, including PAPZIMEOS and the potential to become the preferred product and new